They observed that high levels of MIP-1β may play a role in the pathogenesis of DKD, as MIP-1β inhibition protects against podocyte damage, reduces glomerulosclerosis and fibrosis, and inhibits inflammation activation. Here, CCL4 is linked to diabetic kidney disease.